Eric Schmidt

Reviewing Amgen, Inc. (NASDAQ: AMGN)'s third-quarter results, Cowen said the results were boring but very safe. The firm maintains its Buy rating and $209 price target for the shares of the company. At the time of writing, shares of Amgen were trading down 1.67 percent at $174.54. Analysts...

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) were trading higher by more than 5 percent early Tuesday morning after the U.S. Food and Drug Administration approved its therapy called Soliris (eculizumab) for the treatment of adults with generalized myasthenia gravis (gMG). GMG represents a...

What will a major city look like in the future? Anyone's guess was as good as the other, but we may now have an answer. Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) inked a deal with the city of Toronto to create a digital utopia, The Verge reported. Sidewalk Labs, a subsidiary of Alphabet, will...

Cowen analyst Eric Schmidt thinks the experimental drug TNT009 could change the way investors think about Bioverativ Inc (NASDAQ: BIVV). Schmidt upgraded the company from Market Perform to Outperform and raised its price target from $47 to $80. Bioverative spun off from Biogen Inc (NASDAQ: BIIB)...

Alibaba Group Holding Ltd (NYSE: BABA) founder Jack Ma recently discussed the ways the world is changing and the implications for the global economy in an interview with CNBC. Over the next 30 years, technology will evolve in a way that will make millions of jobs obsolete. While the transition will...

Kite Pharma Inc (NASDAQ: KITE) is preparing to launch Axi-Cel, a chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma patients, later this year. Kite is pursuing an FDA label for patients with relapsed, aggressive and non-transplant eligible forms of the disease, a group of...

Loup Ventures is siding with the machines, concluding on Friday a series of notes analyzing the growth of robotics in the economy. “We believe a cultural shift is underway and robots are playing an increasingly crucial role in our everyday lives,” said analyst Andrew Murphy. Murphy...

Doug Clinton of Loup Ventures says Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Chairman Eric Schmidt is wrong when he says automation won’t wipe out the majority of jobs now performed by inferior humans. “The five-year picture of automation isn’t going to result in mass job loss,...

The Cowen Group has initiated coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with an Outperform rating and $14.48 price target. It's Time To Tackle Orphan Neurological Disorders Until now, the biopharmaceutical industry has mostly ignored orphan neurological disorders due to the difficulty of...

For a biopharmaceutical company, there may be no worse news than the death of a patient receiving treatment during clinical testing. On Monday, shares of Kite Pharma Inc (NASDAQ: KITE) plummeted more than 12 percent after the company disclosed that a patient with brain cancer died following...